AI Trends for PBMs in 2026: The CXO Guide to Cost Control, Compliance, and Competitive Advantage

Introduction: From Experimentation to Enterprise Mandate

For Pharmacy Benefit Manager (PBM) leadership, 2026 is a critical turning point. AI is no longer experimental—it’s the core engine for survival and growth. The new mandate is large-scale, strategic implementation, and it is the primary battleground for market share.

Challenges for PBMs in 2026:

As an executive, you are not just managing a business; you are navigating three core challenges:

The market context is intensifying. With 79% of healthcare organizations already using AI and the broader AI in healthcare market projected to exceed $500 billion by 2033, the technological arms race is well underway. Investors are validating this shift, with PBM-tech platforms achieving valuations over $3.25 billion based on their AI-driven, transparent model. (Source: Grand View Research) 

In 2026, AI is the core engine for survival and growth. It is the primary tool to unlock operational efficiency, guarantee regulatory transparency, and defend your margins. This guide outlines the five AI trends your executive team must champion to secure a competitive advantage. 

The AI landscape is consolidating into five core strategic pillars. Leadership teams who prioritize these areas will be best positioned for growth and operational excellence. 

AI-First Administrative & Clinical Automation

The PBM industry runs on complex, high-friction administrative processes. AI-first automation moves beyond simple scripts to handle end-to-end tasks—like prior authorization (PA) and claims processing—with minimal human intervention. 

Key Applications: Auto-adjudication of claims and PA requests; proactive flagging of potential denials; automated data extraction from clinical notes and faxes. 

The Business Impact: 

• On Financial Performance: This is a direct assault on Selling, General & Administrative (SG&A) expenses. Automating 50-75% of manual PA and claims tasks translates directly to a lower, more sustainable cost-to-serve, permanently improving your operating margin. 
• On Operational Scalability: This strategy breaks the linear link between client volume and headcount. You can absorb new employer groups and member lives without a proportional increase in back-office staff, creating scalable, profitable growth. 
• On Competitive Differentiation: Drastically faster PA turnaround (from days to hours) becomes a critical differentiator in sales pitches to employers, directly impacting member satisfaction and client retention. 

Generative AI for Member & Provider Engagement

This is where AI becomes the new face of your organization, providing intelligent, human-like assistance 24/7 to all stakeholders. 

Key Applications: Member-facing “Copilots” for instant, plain-English answers on benefits, copays, and formulary alternatives. Provider-facing assistants to streamline ePA submissions and check clinical criteria. Internal tools to summarize clinical notes, reducing burnout. 

The Business Impact: 

• On Service & Efficiency: Every query deflected from a live agent to a GenAI “Copilot” is a hard-dollar saving. This transforms your high-volume call center from a major cost center into a high-touch escalation point for complex clinical issues, optimizing your largest service expense. 
• On Client Retention: In a market where PBMs are often commoditized, a superior, frictionless digital experience is a tangible competitive advantage. It’s a key value-add to show employer clients, directly supporting retention and new sales. 
• On Network Relations: Provider-facing assistants reduce “provider abrasion”—a major source of friction and cost. When providers can get instant answers, they stop calling your staff, streamlining the entire network relationship. 

Predictive Analytics for Strategic Cost Management

This is the core of a PBM’s financial strategy: using AI to model, forecast, and actively manage your single biggest liability—drug spend. 

Key Applications: Advanced AI models to accurately forecast the financial impact of pipeline drugs (GLP-1s, gene therapies). AI-powered tools to design sustainable benefit tiers, build smarter formularies, and price risk-sharing contracts with employers. 

The Business Impact: 

• On Underwriting & Margin: This is your primary tool for managing underwriting risk and margin erosion. Accurately forecasting high-cost drug impact before it hits your plans allows you to price employer contracts correctly and avoid margin surprises. 
• On Strategic Client Value: This capability transforms your sales narrative. You move from being a “claims processor” to a “strategic financial partner,” showing an employer, “We’ve modeled your population and can design a plan that saves you X% while ensuring adherence and outcomes.” 
• On Clinical Program Justification: This is how you prove value. By linking cost management to better outcomes (e.g., achieving 90%+ adherence for specialty patients), you provide the data-driven justification for your formulary decisions and clinical programs. 

AI-Driven Clinical Trials & Real-World Evidence

PBMs are moving from being passive consumers of clinical data to active participants in the drug value chain, leveraging their most unique asset. 

Key Applications: Analyzing vast, anonymized, real-world claims data to optimize clinical trial design and recruitment for pharmaceutical partners. Using RWE to inform formulary and value assessments before a high-cost drug hits the market. 

The Business Impact: 

• On Revenue Diversification: This is about data monetization. Your anonymized data is a high-value asset. Creating an RWE business creates a new, high-margin, non-claims-based revenue stream from pharmaceutical manufacturers. 
• On Enterprise Data Value: This is the ultimate justification for investing in a unified data platform. It proves that data is not just an operational expense; it is a core business asset that can be actively monetized. 
• On Negotiating Leverage: This data provides unprecedented leverage. Instead of just reacting to a new drug’s price, you can proactively model its real-world value, strengthening your position in all formulary and rebate discussions. 

AI-Powered Compliance & Transparency

With PBM oversight accelerating and a strong legislative push for drug pricing transparency, AI is becoming a critical tool for governance, risk, and compliance (GRC). 

Key Applications: AI tools to monitor, audit, and report on pricing, rebates, and formulary decisions at scale. Proactive detection of pricing anomalies. Ensuring new AI models (e.g., for PA) are fair, explainable, and compliant with 2026 “consequential decision” regulations. 

The Business Impact: 

• On Enterprise Risk Management: In 2026, “we didn’t know” is not a viable legal defense. AI is the only tool that can proactively monitor 100% of your transactions in real-time to detect anomalies before a state or federal audit. This is your primary defense against massive fines and reputational damage. 
• On Financial Prudence: This is about de-risking the entire enterprise. The financial and reputational cost of a major compliance failure (like those outlined by the HSCC) far exceeds the investment in AI monitoring and governance. 
• On Technology & Data Governance: This mandates a formal AI governance framework. Regulators will demand to know how your AI makes decisions. Your technology strategy must now include “explainability” and “auditability” by default. 

Conclusion: A Pragmatic Path Forward

For PBM leadership, the path forward in 2026 is one of pragmatic, strategic integration. The greatest risk is not in adopting AI, but in assuming your current legacy systems can compete with AI-native competitors. 

This is not about a single, all-at-once replacement of systems. It is about a modular, targeted approach. The goal is to apply AI to the points of greatest business friction and highest ROI—prior authorization, member frustration, cost forecasting, and compliance. 

The PBMs that thrive will be those who view AI not as an IT project, but as a core, C-suite-led business strategy. It is the key to driving margin, guaranteeing compliance, and securing client retention in the new decade. 

How Veltris Helps PBMs Adopt These AI Trends

Veltris provides the pragmatic, modular approach executives need to adopt these AI trends without disrupting core, compliance-heavy systems. We help PBMs Build, Modernize, and Monetize their platforms, mapping our expertise directly to these strategic goals. 

• Adopting AI-Driven Automation We modernize Prior Authorization and Operational Workflows. Our modular AI-driven PA layers and denial management models integrate into your existing stack to reduce manual workload, lower operating costs, and speed up approvals. 
• Delivering GenAI Engagement We transform the Member Experience. Our work on modern portals and conversational AI assistants provides members with instant, self-service answers, dramatically reducing call center load and improving member satisfaction. 
• Enabling Analytics, Compliance: We deliver Data Modernization & Reporting Transparency. PBMs cannot run predictive models, prove compliance, or analyze real-world evidence on fragmented data. 
  • We build unified data foundations to consolidate claims, eligibility, and formulary data. 
  • We deploy Power BI dashboards that give employers real-time, transparent visibility into costs and savings, which is the foundation for both cost management (Trend 3) and regulatory compliance. 
  • This unified data lake becomes the single source of truth required to integrate and analyze real-world evidence for smarter formulary design.